Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
34 hedge funds and large institutions have $73.1M invested in Eiger BioPharmaceuticals, Inc. in 2014 Q1 according to their latest regulatory filings, with 34 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$15.7M |
| 2 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
+$11.2M |
| 3 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$10.2M |
| 4 |
JP Morgan Chase
New York
|
+$5.49M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$4.05M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
V
26
Veritable
Wilmington,
Delaware
| $174K | +$151K | +32 | New |
|
27
Bank of New York Mellon
New York
| $170K | +$151K | +32 | New |
|
|
BIM
28
BlackRock Investment Management
Wilmington,
Delaware
| $169K | +$151K | +32 | New |
|
|
BPC
29
Banque Pictet & Cie
Geneva 73,
Switzerland
| $154K | +$137K | +29 | New |
|
30
California State Teachers Retirement System (CalSTRS)
West Sacramento,
California
| $137K | +$123K | +26 | New |
|
|
TRCT
31
Tower Research Capital (TRC)
New York
| $33K | +$28.4K | +6 | New |
|
32
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $18K | +$18.9K | +4 | New |
|
33
Bank of America
Charlotte,
North Carolina
| $12K | +$9.45K | +2 | New |
|
|
BA
34
BlackRock Advisors
Wilmington,
Delaware
| $11K | +$9.45K | +2 | New |
|
35
Barclays
London,
United Kingdom
| $2K | – | – | – |
|
36
Citigroup
New York
| $2K | – | – | – |
|
|
U
37
UBS
Zurich,
Switzerland
| $1K | – | – | – |
|
EIGR Hedge Fund Activity: Q1 2014 in Review
34 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q1 2014, worth a combined $73.1M.
Buyers outnumbered sellers: 34 funds opened new EIGR positions and 0 closed out — a net gain of 34 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Palo Alto Investors, opening a new position worth an estimated $15.7M.
- 34 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q1 2014, up from 0 in Q4 2013.
- Funds reported $73.1M of Eiger BioPharmaceuticals, Inc. stock for Q1 2014.
- 34 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q1 2014 and 0 closed out, a net change of +34 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q1 2014 was Palo Alto Investors, an estimated $15.7M added.
Based on aggregated 13F filings for Q1 2014.